

**Table S1.** Univariate survival model analysis for OS in 433 patients.

Clinicopathogenic variables	COH cohort (n=433)			
		95% CI		
	HR	Lower	Upper	P-value
Age at diagnosis (years)				
≥65 vs. <65	1.13	0.86	1.48	0.38
Gender				
Male vs. Female	1.13	0.89	1.43	0.32
Sidedness				
Right vs. Left	1.47	1.14	1.89	0.00
<i>RAS</i>				
Mutated vs. Non-mutated	1.15	0.91	1.46	0.24
<i>BRAF<sup>V600E</sup></i>				
Mutated vs. Non-mutated	1.72	1.13	2.62	0.01
<i>APC</i>				
Mutated vs. Non-mutated	0.71	0.55	0.92	0.01
<i>TP53</i>				
Mutated vs. Non-mutated	1.17	0.87	1.58	0.31
<i>SMAD4</i>				
Mutated vs. Non-mutated	1.31	0.95	1.80	0.10

**Table S2.** Univariate survival model analysis for OS in patients with *SMAD4* mutation.

Clinicopathogenic variables	SMAD4-MT cohort (n=70)			
		95% CI		
	HR	Lower	Upper	P-value
<i>RAS</i>				
Mutated vs. Non-mutated	0.98	0.54	1.76	0.94
<i>BRAF<sup>V600E</sup></i>				
Mutated vs. Non-mutated	1.55	0.65	3.68	0.32
<i>APC</i>				
Mutated vs. Non-mutated	0.68	0.38	1.23	0.20
<i>TP53</i>				
Mutated vs. Non-mutated	2.74	1.15	6.52	0.02

**Table S3.** Multivariate survival model analysis for OS in patients without *SMAD4* mutation.

Clinicopathogenic variables	SMAD4-WT cohort (n=363)			
		95% CI		
	HR	Lower	Upper	P-value
<i>RAS</i>				
Mutated vs. Non-mutated	1.26	0.96	1.66	0.10
<i>BRAF<sup>V600E</sup></i>				
Mutated vs. Non-mutated	1.64	0.95	2.84	0.08
<i>APC</i>				
Mutated vs. Non-mutated	0.80	0.58	1.10	0.17
<i>TP53</i>				
Mutated vs. Non-mutated	1.10	0.79	1.53	0.57